Use of genetics and transcriptomics in the diagnosis and treatment of coronary artery disease;Uso de la genética y la transcriptómica en el diagnóstico y tratamiento de la enfermedad coronaria

Revista Espanola de Cardiologia

Volumn 63, Issue 10, 2010, Pages 1123-1126

  Freedman, Jane E ^a   Iafrati, Hannah F ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORONARY ARTERY DISEASE; EDITORIAL; GENETICS; TRANSCRIPTOMICS;

ANTICOAGULANTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; GENE EXPRESSION PROFILING; GENETIC TESTING; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; WARFARIN;

EID: 78649262505     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(10)70243-8     Document Type: Editorial

References (20)

1. H. Hakonarson, S.F. Grant, J.P. Bradfield, L. Marchand, C.E. Kim, and J.T. Glessner A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene Nature 448 2007 591 594 (Pubitemid 47206935)
2. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-78.
3. S. Kathiresan, O. Melander, C. Guiducci, A. Surti, N.P. Burtt, and M.J. Rieder Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans Nat Genet 40 2008 189 197
4. D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T.B. Ferguson, and K. Flegal Heart Disease and Stroke Statistics - 2009 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 2009 480 486
5. A.L. Frelinger 3rd, M.I. Furman, M.D. Linden, Y. Li, M.L. Fox, and M.R. Barnard Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance Circulation 113 2006 2888 2896
6. C.J. O'Donnell, M.G. Larson, D. Feng, P.A. Sutherland, K. Lindpaintner, and R.H. Myers Genetic and environmental contributions to platelet aggregation: the Framingham heart study Circulation 103 2001 3051 3056
7. J.E. Freedman, M.G. Larson, K. Tanriverdi, C.J. O'Donnell, K. Morin, and A.S. Hakanson Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham Heart Study Circulation 122 2010 119 129
8. J. Huang, Z. Liang, B. Yang, H. Tian, J. Ma, and H. Zhang Derepression of microRNA-mediated protein translation inhibition by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members J Biol Chem 282 2007 33632 33640
9. T.M. Rana Illuminating the silence: understanding the structure and function of small RNAs Nat Rev Mol Cell Biol 8 2007 23 36
10. J.L. Anderson, B.D. Horne, S.M. Stevens, A.S. Grove, S. Barton, and Z.P. Nicholas Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation Circulation 116 2007 2563 2570
11. B. Giusti, A.M. Gori, R. Marcucci, C. Saracini, I. Sestini, and R. Paniccia Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients Pharmacogenet Genomics 17 2007 1057 1064
12. K.A. Kim, P.W. Park, S.J. Hong, and J.Y. Park The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance Clin Pharmacol Ther 84 2008 236 242
13. J.S. Hulot, A. Bura, E. Villard, M. Azizi, V. Remones, and C. Goyenvalle Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects Blood 108 2006 2244 2247
14. D.J. Angiolillo, A. Fernández-Ortiz, E. Bernardo, C. Ramírez, U. Cavallari, and E. Trabetti Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel Arterioscler Thromb Vasc Biol 26 2006 1895 1900
15. D. Trenk, W. Hochholzer, M.F. Fromm, L.E. Chialda, A. Pahl, and C.M. Valina Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or baremetal stents J Am Coll Cardiol 51 2008 1925 1934
16. C. Frere, T. Cuisset, P.E. Morange, J. Quilici, L. Camoin-Jau, and N. Saut Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome Am J Cardiol 101 2008 1088 1093
17. T. Simon, C. Versuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Meneveau Genetic determinants of clopidogrel response and cardiovascular events N Engl J Med 360 2009 363 375
18. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 22;360:354-62.
19. D.R. Holmes Jr, G.J. Dehmer, S. Kaul, D. Leifer, P.T. O'Gara, and C.M. Stein ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "Boxed Warning". A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Circulation 2010 [Epub ahead of print]
20. M. Gilard, B. Arnaud, J.C. Cornily, G. Le Gal, K. Lacut, and G. Le Calvez Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, doubleblind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260